Please assess the completion status of the following clinical trial:

Trial Title: AVAPERL1 Study: A Study of Avastin (Bevacizumab) With or Without Pemetrexed as Maintenance Therapy After Avastin in First Line in Patients With Non-Squamous Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* adults \>/=18 years of age~* inoperable, locally advanced, metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC)~* at least 1 measurable lesion meeting RECIST criteria~* ECOG performance status 0-2~* adequate hematological, liver and renal function~Exclusion Criteria:~* prior chemotherapy or treatment with another systemic anti-cancer agent~* malignancies other than NSCLC within 5 years prior to randomization, except for adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer or DCIS~* evidence of tumor invading major blood vessels~* current or recent use of aspirin (\>325mg/day) or full-dose anticoagulants or thrombolytic agents for therapeutic purposes~* history of haemoptysis \>/=grade 2~* clinically significant cardiovascular disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1 (Type: EXPERIMENTAL): None
- Part 2A (Type: EXPERIMENTAL): None
- Part 2B (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).